TRANSITIONS OPTICAL OFFERS TRANSITIONS CERTIFICATION PROGRAM ONLINE
Transitions Optical has launched a new online training resource - the Transitions Certification Program. The new Transitions Certification Program offers two ways to participate: one for
individual eyecare professionals (ECPs) to become a Transitions Specialist and another for eyecare practices to become a Transitions Certified Provider.
• ECPs can become a Transitions Specialist by completing the required online training and passing a quiz. Once completed, they will receive a certificate, a lapel pin and a social post they can use.
• To become a Transitions Certified Provider, practices must have three ECPs from their office become Transitions Specialists. After successfully becoming a Transitions Certified Provider, practices earn a window cling to display in their office, social posts they can use and a specialised icon on the Transitions.com Eyecare Practice Locator.
o In 2019 over 200,000 consumers searched for an eyecare professional using the Eyecare Practice Locator on Transitions.com. The specialized icon will allow Transitions Certified Providers to stand out on Transitions.com to consumers using the Eyecare Practice Locator.
ECPs and eyecare practices interested in the Transitions Certified Provider Program can view the training resources, read the full program requirements and earn their certification at www.transitionscertified.com/en-ca
I’M JUST SAYING NOVEMBER 2020
By Robert Dalton, OAC Executive Director
Opticians who attended the Ontario Opticians Association online event on October 18th, this will not be news to you. I have to say though, I was quite astounded by the announcement that Ontario Opticians would no longer have their professional learning accredited if the learning made any mention of a specific product. How is it that one regulator in Canada can be so different from another? Even from ALL others? It is a bit unbelievable to think that every other Regulatory College in Canada recognizes the value of an Optician being educated in every product available on the market.
AVOID THE END-OF-YEAR RUSH BY RENEWING YOUR MEMBERSHIP NOW
2020 comes to an end. What was supposed to be the year of vision will mark our memories forever but unfortunately for other reasons. This may be a paradox, but our community is now closer than ever. Your commitment to your provincial and national associations helped the Opticians Association of Canada (OAC) support all Opticians across Canada during these difficult times particularly by reducing Opticians’ expenses through the provision of free live and on demand continuing education.
In 2021, the OAC will continue its mission and to help you meet your professional goals by offering tangible benefits, including free essential services, such as professional liability insurance and free professional learning opportunities.
The OAC team is ready to help you renew your 2021 OAC Membership.
We sincerely hope that you will join us for another year of great programs and professional development.
HOW TO DISINFECT VARIOUS EYEWEAR MATERIALS TO HELP PREVENT COVID-19
By Sara Moshurchak, Head Honcho, Frame Designer, Optical Wizard
In a world with COVID-19, we don’t want to touch our eyes, nose, mouth and face. But what about our eyewear? It’s important to clean your frames more frequently than you usually would. These are methods based on 19 years of experience and practices we use at Mosh Framemakers working with a wide range of materials and seeing the long term effects of various cleaning products.
THE FUTURE IS BRIGHT: HEALTH CANADA APPROVES FIRST SIGHT-RESTORING GENE THERAPY FOR INHERITED EYE DISEASES
TORONTO, October 15, 2020 – On October 14, 2020, Health Canada announced their approval of the first sight-restoring innovative treatment voretigene neparvovec (Brand name: Luxturna). This announcement is the first targeted gene therapy approved in Canada for any disease. This treatment is specifically for individuals with the inherited blinding eye diseases retinitis pigmentosa (RP) or Leber congenital amaurosis (LCA) resulting from mutations in the RPE65 gene that leads to vision loss and eventually blindness.
"Lives will be transformed in Canada because of approval of this research-delivered groundbreaking treatment. For the first time, it means we have a treatment option – bringing hope to families affected by genetic mutations causing blindness and to everyone in the vision loss community." says Doug Earle, President & CEO, Fighting Blindness Canada.